Rigor Reviewed

Rigor-Reviewed Manuscript

Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial.

Name: Αlpha¹ Rigor Record — Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial.
Item: Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial.
Rating: 100
Author: Αlpha¹

Rampal RK, Grosicki S, Chraniuk D, Abruzzese E, Bose P, Gerds AT, Vannucchi AM, Palandri F, Lee SE, Gupta V, Lucchesi A, Oh ST, Kuykendall AT, Patriarca A, Álvarez-Larrán A, Mesa R, Kiladjian JJ, Talpaz M, Scandura JM, Lavie D, Harris M, Kays SK, Li Q, Boxhammer R, Brown B, Jegg AM, Harrison CN, Mascarenhas J

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 3★ (Adequate), 0 critical, 0 high issues for “Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Problems surfaced4 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions3

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a rigorously designed and transparently reported phase 3 randomized controlled trial. The manuscript demonstrates strong scientific premise, robust methodology, and comprehensive reporting across all eight rigor dimensions. Only minor copyedit issues and a few reporting refinements are noted.

Both reviewers independently scored all eight dimensions as 'pass' with high confidence, and their evidence was consistent. The study type is interventional (phase 3 RCT). Non-applicable sub-criteria (e.g., animal housing, cell line authentication) were excluded. The statistics verification covered only a subset of tests (1 recomputed consistently); the full statistical analysis was not independently re-analyzed.

7 major claims checked against the paper's own evidence: 2 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Recomputed 1 test: 1 consistent, 0 inconsistent; 1 via agent-written checks.

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions8 pass

The introduction cites prior work on JAK inhibitor monotherapy limitations and preclinical BET inhibition studies, and references the phase 2 MANIFEST study results. The rationale linking BET and JAK inhibition to improved outcomes is logically presented. Limitations of prior research (e.g., short-term treatment effects) are acknowledged and addressed by the study design.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The study clearly establishes the scientific premise with prior work, a logical rationale, and addresses limitations of prior research.

Evidence

paraphrase[Introduction, paragraphs 1-3]

“JAK inhibitor monotherapy is the standard of care for myelofibrosis in patients with splenomegaly and/or symptoms. However, JAK inhibitors do not consistently resolve pathobiological features, such as molecular markers of clonal burden and disrupted bone marrow morphology, particularly with short-term treatment.”

paraphrase[Introduction, paragraph 3]

“In the same model, BET inhibition with JQ1 in combination with JAK inhibition (using ruxolitinib) demonstrated greater reductions in these parameters than achieved by either drug alone.”

paraphrase[Discussion, paragraph 1]

“Indeed, the spleen response rate in patients treated with pelabresib–ruxolitinib was approximately double that seen with placebo–ruxolitinib in the MANIFEST-2 study (35.2%; P < 0.001), and in previous studies of JAK inhibitor monotherapy (ranging from 18% to 42%).”

PASSReviewer 2· 95% conf

The study establishes a strong scientific premise by citing prior research on JAK inhibitor limitations, BET inhibition rationale, and phase 2 data, with a clear hypothesis.

Evidence

paraphrase[Introduction, paragraphs 1-3]

“JAK inhibitor monotherapy is the standard of care for myelofibrosis in patients with splenomegaly and/or symptoms. However, JAK inhibitors do not consistently resolve pathobiological features... Therefore, an unmet medical need persists due to limited depth and durability of clinical response.”

paraphrase[Introduction, paragraph 4]

“Data from the phase 2 MANIFEST study (NCT02158858) demonstrated substantial and durable improvements in splenomegaly and symptoms with pelabresib plus ruxolitinib in JAK inhibitor-naive patients with myelofibrosis (n=84): a reduction in spleen volume of ≥35% was observed in 68% of patients.”

paraphrase[Introduction, paragraph 3]

“In the same model, BET inhibition with JQ1 in combination with JAK inhibition (using ruxolitinib) demonstrated greater reductions in these parameters than achieved by either drug alone.”

Randomization was centralized with stratification, blinding was double-blind, power analysis was provided, and inclusion/exclusion criteria were pre-specified. The analysis population (ITT) and missing data handling (multiple imputation) are described, satisfying outlier handling. Controls are inherent in the placebo arm.

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous with adequate randomization, blinding, power analysis, and inclusion/exclusion criteria.

Evidence

paraphrase[Methods, Study design]

“patients were randomized 1:1 to pelabresib plus ruxolitinib or placebo plus ruxolitinib, by a centralized interactive voice response/interactive web response system. Stratification was based on DIPSS category, platelet count and spleen volume.”

direct quote[Methods, Study design]

“All patients, investigators and the sponsor were blinded to treatment allocation with study drugs packaged identically.”